Triheptanoin
UX007-CL302
Phase 3 small_molecule active
Quick answer
Triheptanoin for Long-chain Fatty Acid Oxidation Disorders (LC-FAOD) is a Phase 3 program (small_molecule) at Ultragenyx Pharmaceutical with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Ultragenyx Pharmaceutical
- Indication
- Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active